- Scrip 100: Buzzing biotechs outrace sluggish pharma
- US Capitol Capsule: Rare disease sector matures; FDA keeping pace?
- Reaping in due season? R&D trends and novel drug launches
- 1Q EARNINGS: Pfizer highlights AstraZeneca deal as sales sink
ANALYSIS Other Informa Analysis
COMMENT Other Informa Comment
- UCB's Lode Dewulf: 'We can and should talk to patients'
- Leadership lesson: How to slim down and shape up, Kress style